| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-9072, USA
2 Department of Internal Medicine, University of Texas Southwestern Medical Center
3 Academic Computing Services, University of Texas Southwestern Medical Center
Dr Ashfaq email: ashfaq.raheela{at}pathology.swmed.edu Aim—To evaluate the clinical usefulness of three commercially available assays for Her-2/neu oncogene and protein measurements. The Her-2/neu protein is overexpressed, mostly as a result of gene amplification, in 20–30% of human breast cancers, and has been shown to have prognostic and predictive value for treatment with chemotherapy or the new monoclonal antibody, Herceptin.
Methods—An immunohistochemistry (IHC) assay using the Dako polyclonal antibody A0485, which measures the Her-2/neu protein, was compared with two new Food and Drug Administration (FDA) approved fluorescence in situ hybridisation (FISH) assays—INFORMTM and PathVysionTM, in a cohort of 52 formalin fixed, paraffin wax embedded breast tissues. These tissues were selected randomly from 84 consecutive infiltrating breast cancer specimens, which were first stratified according to the Her-2/neu protein levels as measured by IHC.
Results—The two FISH assays achieved a 98% concordance rate: 14 specimens (27%) showed Her-2/neu gene amplification and 37 specimens (71%) showed no Her-2/neu gene amplification. The PathVysion assay had certain advantages over the INFORM assay. In contrast, the IHC assay detected Her-2/neu overexpression in a high percentage of cases, including 13 high positive specimens (25%) and 13 medium positive specimens (25%). Although 10 of these 13 IHC high positive specimens showed gene amplification by FISH, nine of 13 IHC medium positive specimens showed no gene amplification. Statistical analyses showed that the differences between IHC and FISH assays were primarily in the specimens with medium positive IHC, but negative FISH results.
Conclusions—Because of the increasing importance of the Her-2/neu oncogene and oncoprotein in the clinical management of patients with breast cancer, the accurate and consistent evaluation of Her-2/neu status is crucial. This study suggests that the best approach is to combine both IHC and FISH assays; that is, to use the IHC assay as a triage step, followed by the PathVysion FISH assay to analyse the IHC medium and high positive cases.
Key Words: Her-2/neu • breast cancer • fluorescence in situ hybridisation
This article has been cited by other articles:
|
|
 |
|
  H. Tawbi, D. Thomas, D. R. Lucas, J. S. Biermann, S. M. Schuetze, A. L. Hart, R. Chugh, and L. H. Baker Epidermal Growth Factor Receptor Expression and Mutational Analysis in Synovial Sarcomas and Malignant Peripheral Nerve Sheath Tumors Oncologist, April 1, 2008; 13(4): 459 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Arnould, P. Arveux, J. Couturier, M. Gelly-Marty, C. Loustalot, F. Ettore, C. Sagan, M. Antoine, F. Penault-Llorca, B. Vasseur, et al. Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification Clin. Cancer Res., November 1, 2007; 13(21): 6404 - 6409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Winer, J. R. Harris, B. L. Smith, H. A. D'Alessandro, and E. F. Brachtel Case 32-2007 -- A 62-Year-Old Woman with a Second Breast Cancer N. Engl. J. Med., October 18, 2007; 357(16): 1640 - 1648. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Layman, D. G. Thomas, K. A. Griffith, J. B. Smerage, M. A. Helvie, M. A. Roubidoux, K. M. Diehl, L. A. Newman, M. S. Sabel, J. A. Hayman, et al. Neoadjuvant Docetaxel and Capecitabine and the Use of Thymidine Phosphorylase as a Predictive Biomarker in Breast Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4092 - 4097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Dal Lago, V. Durbecq, C. Desmedt, R. Salgado, T. Verjat, L. Lespagnard, Y. Ma, I. Veys, A. Di Leo, C. Sotiriou, et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol. Cancer Ther., October 1, 2006; 5(10): 2572 - 2579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S-Y Kong, J H Kang, Y Kwon, H-S Kang, K-W Chung, S H Kang, D H Lee, J Ro, and E S Lee Serum HER-2 concentration in patients with primary breast cancer J. Clin. Pathol., April 1, 2006; 59(4): 373 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z-H Xian, S-H Zhang, W-M Cong, W-Q Wu, and M-C Wu Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma J. Clin. Pathol., May 1, 2005; 58(5): 500 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhu, L. W. C. Chow, W. T. Y. Loo, X.-Y. Guan, and M. Toi Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial Clin. Cancer Res., July 15, 2004; 10(14): 4639 - 4644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Wiley and L. K. Diaz High-Quality HER-2 Testing: Setting a Standard for Oncologic Biomarker Assessment JAMA, April 28, 2004; 291(16): 2019 - 2020. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Elkin, M. C. Weinstein, E. P. Winer, K. M. Kuntz, S. J. Schnitt, and J. C. Weeks HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis J. Clin. Oncol., March 1, 2004; 22(5): 854 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I O Ellis, J Bartlett, M Dowsett, S Humphreys, B Jasani, K Miller, S E Pinder, A Rhodes, and R Walker Best Practice No 176: Updated recommendations for HER2 testing in the UK J. Clin. Pathol., March 1, 2004; 57(3): 233 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Gjerdrum, B. S. Sorensen, E. Kjeldsen, F. B. Sorensen, E. Nexo, and S. Hamilton-Dutoit Real-Time Quantitative PCR of Microdissected Paraffin-Embedded Breast Carcinoma: An Alternative Method for HER-2/neu Analysis J. Mol. Diagn., February 1, 2004; 6(1): 42 - 51. [Abstract] [Full Text]
|
|
|
|
|
|
P. Heinmoller, C. Gross, K. Beyser, C. Schmidtgen, G. Maass, M. Pedrocchi, and J. Ruschoff HER2 Status in Non-Small Cell Lung Cancer: Results from Patient Screening for Enrollment to a Phase II Study of Herceptin Clin. Cancer Res., November 1, 2003; 9(14): 5238 - 5243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy Oncologist, August 1, 2003; 8(4): 307 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Dhaini, D. G. Thomas, T. J. Giordano, T. D. Johnson, J. S. Biermann, K. Leu, P. F. Hollenberg, and L. H. Baker Cytochrome P450 CYP3A4/5 Expression as a Biomarker of Outcome in Osteosarcoma J. Clin. Oncol., July 1, 2003; 21(13): 2481 - 2485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Selvarajan, B.-H. Bay, A. Choo, K.-L. Chuah, C. R. Sivaswaren, S.-L. Tien, C.-Y. Wong, and P.-H. Tan Effect of Fixation Period on HER2/neu Gene Amplification Detected by Fluorescence In Situ Hybridization in Invasive Breast Carcinoma J. Histochem. Cytochem., December 1, 2002; 50(12): 1693 - 1696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Bernard and C. T. Wittwer Real-Time PCR Technology for Cancer Diagnostics Clin. Chem., August 1, 2002; 48(8): 1178 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Thomas, T. J. Giordano, D. Sanders, J. S. Biermann, and L. Baker Absence of HER2/neu Gene Expression in Osteosarcoma and Skeletal Ewing's Sarcoma Clin. Cancer Res., March 1, 2002; 8(3): 788 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J D Oxley, M H Winkler, D A Gillatt, and D S Peat Her-2/neu oncogene amplification in clinically localised prostate cancer J. Clin. Pathol., February 1, 2002; 55(2): 118 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. Funkhouser and K. Kaiser-Rogers Significance of, and Optimal Screening for, HER-2 Gene Amplification and Protein Overexpression in Breast Carcinoma Ann. Clin. Lab. Sci., October 1, 2001; 31(4): 349 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Roses Pharmacogenetics Hum. Mol. Genet., October 1, 2001; 10(20): 2261 - 2267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S S Cross Observer accuracy in estimating proportions in images: implications for the semiquantitative assessment of staining reactions and a proposal for a new system J. Clin. Pathol., May 1, 2001; 54(5): 385 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Eisenhauer From the Molecule to the Clinic -- Inhibiting HER2 to Treat Breast Cancer N. Engl. J. Med., March 15, 2001; 344(11): 841 - 842. [Full Text] [PDF]
|
|
|
|
|
|
I O Ellis, M Dowsett, J Bartlett, R Walker, T Cooke, W Gullick, B Gusterson, E Mallon, and P Barrett Lee Recommendations for HER2 testing in the UK J. Clin. Pathol., December 1, 2000; 53(12): 890 - 892. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |
